APA

Estrada V., De Villar N. G. P., Larrad M. T. M., López A. G., Fernández C. & Serrano-Rios M. (20020624). Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chicago

Estrada V, De Villar N G P, Larrad M T Martínez, López A González, Fernández C and Serrano-Rios M. 20020624. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Harvard

Estrada V., De Villar N. G. P., Larrad M. T. M., López A. G., Fernández C. and Serrano-Rios M. (20020624). Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MLA

Estrada V, De Villar N G P, Larrad M T Martínez, López A González, Fernández C and Serrano-Rios M. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 20020624.